Pediatric Brain Tumor Market Highlights

The pediatric brain tumor market research report shows that the industry is growing at the CAGR of 6.8% during the forecast period and expected to reach USD 1843.7 Million by 2022-2030.

The global Pediatric brain Tumor Market has been evaluated as a steady growing market and it is expected to continue growing in the near future. Increasing cases of pediatric brain tumors are leading the market growth. Various research initiatives taken by government, NGOs and healthcare providers are major driving forces of this market.

Key companies to watch out for:
On curious, Belgium based biotech start up launched a phase I/II a trial for an antibody to fight pediatric brain tumors.
Canada based pharmaceutical company DelMar Pharmaceuticals, Inc. focused on research development and commercialization of new cancer therapies. In The company released a press note and claimed that their new chemotherapy treatment VAL-083 (dianhydrogalactitol) can be effective hemotherapeutic alternative for pediatric brain tumors.

Regional Analysis:

Considering the global scenario of the pediatric brain tumor market, North America was holding the largest market share in global pediatric brain tumor market. Due to funding for R&D, high income and advanced healthcare, US is dominating North America market. European market is the second largest market for pediatric brain tumor. Increasing prevalence and awareness of disorder are key drivers for the growth of Asia Pacific pediatric brain tumor market. Middle East and Africa Pediatric brain tumor market is expected to limited growth it is mostly because of lack of knowledge of disorder and treatment, limited access to required healthcare facilities etc.


Global pediatric brain tumor market has been segmented on the basis of types which comprises of gliomas, mixed neuronal-glial tumors, embryonal tumors, choroid plexus papilloma/carcinoma, tumors arising from non-neuroepithelial tissue, meningeal tumors, and others. Gliomas is further sub-segmented into astrocytoma, malignant gliomas, and others. Mixed neuronal-glial tumors are further sub-segmented into ganglioglioma, subependymal giant cell tumor, pleomorphic xanthoastrocytoma, and others. Embryonal tumors are further sub-segmented into primitive neuroectodermal tumor (PNET), atypical teratoid/rhabdoid tumor, and others. Tumors arising from non-neuroepithelial tissue are further sub-segmented into craniopharyngioma, pineal region tumors, and others.

On the basis of diagnosis, it is segmented into physical exam, Imaging tests, brain or spinal cord tumor biopsy, lumbar puncture (spinal tap), blood and urine tests, and others. Imaging tests are further sub-segmented into Magnetic Resonance Imaging (MRI) scan, Computed Tomography (CT) scan, Positron Emission Tomography (PET) scan, Angiogram, and others. Magnetic Resonance Imaging (MRI) scan is further sub-segmented into Magnetic Resonance Angiography (MRA), Magnetic Resonance Spectroscopy (MRS), Magnetic Resonance Perfusion, Functional MRI (fMRI), and others. Brain or spinal cord tumor biopsy is further sub-segmented into stereotactic needle biopsy, craniotomy, and other.

On the basis of treatment, the market has been segmented into surgery, therapies, drug treatment, and others. Surgery is further sub-segmented into surgical biopsy, resection (removal), shunt placement/revision, and others. Therapies includes radiation therapy, chemotherapy, targeted therapy, and others. Chemotherapy includes carboplatin, carmustine (BCNU), cisplatin, cyclophosphamide, etoposide, lomustine (CCNU), methotrexate, temozolomide, thiotepa, vincristine, and others. Drug treatment is further sub-segmented into corticosteroids, anti-seizure drugs (anti-epileptics), hormones, and others. 

On the basis of end user, it is segmented into hospitals and clinics, medical research centers, academic institutes, and others.

Major Players in pediatric brain tumor market:

There are plenty of large and small players mentioned in the pediatric brain tumor market report which operate in this market: Abbott. (US), AbbVie Inc. (US), Akorn, Inc. (US), Agios, Inc. (US), Baxter (US), Bayer AG (US), Epizyme, Inc. (US), Novartis AG (Switzerland), Mylan N.V. (US), and others

Major players are funding large amount of money on research and also adopting collaboration strategy to capture the major market share. The main business of major players are coming from developed regions like North America and Europe. Due to rising of products and therapies, these players are looking at Asia Pacific region for future prospective.
Companies are highly dependent on FDA approvals. Recently, world’s one of the top pharmaceutical company, AbbVie Received FDA grant for rare pediatric disease designation for ABT-414, that used for the treatment of pediatric brain tumor.

About Market Research Future:

Market Research Future (MRFR) is a global market research company that takes pride in its services, offering a complete and accurate analysis with regard to diverse markets and consumers worldwide. Market Research Future has the distinguished objective of providing the optimal quality research and granular research to clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help answer your most important questions.

Contact Us:

Market Research Future (Part of Wantstats Research and Media Private Limited)

99 Hudson Street, 5Th Floor

New York, NY 10013

United States of America

+1 628 258 0071 (US)

+44 2035 002 764 (UK)